Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients

BACKGROUND: Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, comprising less than 2% of non-Hodgkin’s lymphomas, and affecting mainly middle-aged and elderly patients with a median survival of >10 years. The typical clinical features of SMZL include splenome...

Descripción completa

Detalles Bibliográficos
Autores principales: Castelli, Roberto, Gidaro, Antonio, Deliliers, Giorgio Lambertenghi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928534/
https://www.ncbi.nlm.nih.gov/pubmed/27413523
http://dx.doi.org/10.4084/MJHID.2016.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928534/
https://www.ncbi.nlm.nih.gov/pubmed/27413523
http://dx.doi.org/10.4084/MJHID.2016.030

Ejemplares similares